rupatadine has been researched along with luteolin in 2 studies
Studies (rupatadine) | Trials (rupatadine) | Recent Studies (post-2010) (rupatadine) | Studies (luteolin) | Trials (luteolin) | Recent Studies (post-2010) (luteolin) |
---|---|---|---|---|---|
116 | 43 | 62 | 2,402 | 15 | 1,648 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Theoharides, TC | 1 |
Antonopoulou, S; Demopoulos, C; Theoharides, TC | 1 |
1 review(s) available for rupatadine and luteolin
Article | Year |
---|---|
COVID-19, microthromboses, inflammation, and platelet activating factor.
Topics: Antiviral Agents; Blood Platelets; COVID-19; Cyproheptadine; Disseminated Intravascular Coagulation; Gene Expression Regulation; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Lung; Luteolin; Mast Cells; Platelet Activating Factor; Pulmonary Embolism; Quercetin; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
1 other study(ies) available for rupatadine and luteolin
Article | Year |
---|---|
Potential association of mast cells with coronavirus disease 2019.
Topics: Cell Communication; Cholecalciferol; COVID-19; COVID-19 Drug Treatment; Cromolyn Sodium; Cyproheptadine; Cytokines; Famotidine; Histamine; Histamine Antagonists; Humans; Lung; Luteolin; Macrophages; Mast Cells; SARS-CoV-2; Severity of Illness Index; Substance P | 2021 |